Answers are grounded in this paper and cite their sources.
OBJECTIVE: To confirm the safety and performance of Vectorio®, a Lipiodol-resistant mixing and injection system for conventional trans-arterial chemoembolization (cTACE) in clinical practice. MATERIALS AND METHODS: This was a prospective, observational, single-arm, multicenter post-market clinical follow-up study conducted between August 2022 and May 2023 (NCT05316077). Adult patients with confirmed hepatocellular carcinoma (HCC) and eligible for cTACE were considered for enrollment. The leakage/breakage rate and the technical performance of Vectorio®, assessed as the ease of use, were evaluated. Adverse events (AE) and device deficiencies were collected up to 24 h after the procedure. RESULTS: The study included 50 patients (76.0 % male; mean ± SD age: 69.1 ± 9.6 years) with intermediate-stage HCC. One case of leakage, resulting from a user error, was reported. The resulting leakage/breakage rate of Vectorio® was 2.0 % (1/50; 95 %CI: [0.4---10.5]). The usability of the device was evaluated as 'easy' or 'very easy' for all the assessed characteristics except for three procedures (6.0 %) during which the disconnection of the syringes from the stopcock, was deemed to be difficult. A total of 7 AEs of mild or moderate intensity were observed in 6 patients. None were related to the device, and none were serious. Study limitations include: small sample size, absence of comparator, and short-follow up period. CONCLUSIONS: This study supports the safety and performance of Vectorio® for the mixing and injection of the Lipiodol/chemotherapeutic agent emulsion for cTACE.
No takes yet. Share an insight, caveat, or question.
Loffroy et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: